COR Therapeutics, Inc. Announces Receipt of $24 Million Milestone Payment.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--June 9, 1998-- COR Therapeutics, Inc. (Nasdaq:CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) announced that the Company has received a $24 million milestone payment from Schering-Plough Corporation. This milestone payment is in connection with marketing approval of INTEGRILIN(TM) (eptifibatide) in the United States. INTEGRILIN(TM) is now available for the treatment of patients with acute coronary syndrome acute coronary syndrome n. A sudden, severe coronary event that mimics a heart attack, such as unstable angina. acute coronary syndrome (unstable angina and non-Q-wave myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or simply angioplasty, is a therapeutic procedure to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. (PCI (1) (Payment Card Industry) See PCI DSS. (2) (Peripheral Component Interconnect) The most widely used I/O bus (peripheral bus). ). INTEGRILIN(TM) is also available for the treatment of patients undergoing PCI who do not present with an acute coronary syndrome. INTEGRILIN(TM) has the broadest range of indications in this new class of drugs known as GP IIb-IIIa inhibitors. Bleeding is the most common complication encountered during INTEGRILIN(TM) therapy. COR and Schering-Plough Corporation are worldwide partners for INTEGRILIN(TM). Both companies will market and sell the drug in the United States. COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· , deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. and restenosis.In addition to the historical information contained herein, this press release contains forward-looking statements that are subject to risks and uncertainties. A full discussion of COR Therapeutics, Inc.'s operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, are discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-Q for the quarter ended March 31, 1998, and Report on Form 10-K for the year ended December 31, 1997.
CONTACT: COR Therapeutics, Inc. Burns McClellan, Inc.
Laura A. Brege Lisa Burns (Investors)
Jacquelyn A. Jeffries Jonathan M. Nugent
(650) 244-6893 (212) 213-0006
Mike Sinclair (Media)
(415) 352-6262
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion